KNTE

Kinnate Biopharma Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Kinnate Biopharma Inc Stock Price

Vitals

Today's Low:
$8.4600
Today's High:
$8.9800
Open Price:
$8.5600
52W Low:
$5.75
52W High:
$26.05
Prev. Close:
$8.6000
Volume:
81932

Company Statistics

Market Cap.:
$0.375 billion
Book Value:
6.21
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-18.1%
Return on Equity TTM:
-29.7%

Company Profile

Kinnate Biopharma Inc had its IPO on 2020-12-03 under the ticker symbol KNTE.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Kinnate Biopharma Inc has a staff strength of 0 employees.

Stock update

Shares of Kinnate Biopharma Inc opened at $8.56 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $8.46 - $8.98, and closed at $8.49.

This is a -1.28% slip from the previous day's closing price.

A total volume of 81,932 shares were traded at the close of the day’s session.

In the last one week, shares of Kinnate Biopharma Inc have increased by +6.13%.

Kinnate Biopharma Inc's Key Ratios

Kinnate Biopharma Inc has a market cap of $0.375 billion, indicating a price to book ratio of 1.405 and a price to sales ratio of -.

In the last 12-months Kinnate Biopharma Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.105 billion. The EBITDA ratio measures Kinnate Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Kinnate Biopharma Inc’s operating margin was 0% while its return on assets stood at -18.1% with a return of equity of -29.7%.

In Q2, Kinnate Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Kinnate Biopharma Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-2.27 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kinnate Biopharma Inc’s profitability.

Kinnate Biopharma Inc stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of -1.483. Its price to sales ratio in the trailing 12-months stood at -.

Kinnate Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Kinnate Biopharma Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Kinnate Biopharma Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Kinnate Biopharma Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Kinnate Biopharma Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Kinnate Biopharma Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$8.49
52-Week High
$26.05
52-Week Low
$5.75
Analyst Target Price
$34.14

Kinnate Biopharma Inc stock is currently trading at $8.49 per share. It touched a 52-week high of $26.05 and a 52-week low of $26.05. Analysts tracking the stock have a 12-month average target price of $34.14.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Kinnate Biopharma Inc

The stock symbol (also called stock or share ticker) of Kinnate Biopharma Inc is KNTE

The IPO of Kinnate Biopharma Inc took place on 2020-12-03

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$0.89
0
+0.45%
$3
0.1
+3.45%
$11.31
-0.1
-0.88%
$0.78
0
+0.15%
$46.1
-2.14
-4.44%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. The company is headquartered in San Diego, California.

Address

11975 EL CAMINO REAL, STE 101, SAN DIEGO, CA, US